The novel multitarget stool RNA test (ColoSense) showed high sensitivity for detecting colorectal neoplasia(new, uncontrolled growth of cells) among adults ages 45 and older, according to the phase III prospective CRC-PREVENT trial.
Novel Stool RNA Test More Sensitive for Detecting Colon Cancer Versus FIT
Lynch Syndrome Ireland 